Table 2.

Characteristics of female breast cancer patients registered in the Biobank Japan Project within 90 days after diagnosis grouped according to invasive status.

	Invasive status
	Non-invasive type (n = 246)		Invasive type (n = 1544)
	n	%	n	%
Age at study entry
20–29 yr	1	0.4	9	0.6
30–39 yr	29	11.8	111	7.2
40–49 yr	80	32.5	399	25.8
50–59 yr	73	29.7	453	29.3
60–69 yr	51	20.7	367	23.8
70–79 yr	11	4.5	170	11.0
80–89 yr	1	0.4	31	2.0
≥90 yr	0	0.0	4	0.3
Body mass index
<18.5 kg/m2	31	12.7	134	8.8
18.5–24.9 kg/m2	175	71.7	1046	68.9
≥25.0 kg/m2	38	15.6	339	22.3
Unknown	2		25
Smoking habit
Never	192	78.0	1174	76.3
Ever (current/former)	54	22.0	364	23.7
Unknown	0		6
Alcohol drinking habit
Never	142	57.7	891	58.0
Ever (current/former)	104	42.3	644	42.0
Unknown	0		9
History of mastopathy
Absence	243	98.8	1526	98.8
Presence	3	1.2	18	1.2
Family history of breast cancer
Absence	219	89.0	1353	87.6
Presence	27	11.0	191	12.4
Stage
0	99	51.3	37	3.6
Unclassified	4	2.1	3	0.3
I	57	29.5	532	51.7
IIA	31	16.1	348	33.8
IIB	1	0.5	69	6.7
IIIA	1	0.5	15	1.5
IIIB	0	0.0	15	1.5
IIIC	0	0.0	4	0.4
IV	0	0.0	7	0.7
Unknown	53		514
Serum CEA level
<5 ng/mL	233	96.3	1424	95.3
≥5 ng/mL	9	3.7	70	4.7
Unknown	4		50
Serum CA15-3 level
<27 U/mL	236	98.7	1449	97.3
≥27 U/mL	3	1.3	40	2.7
Unknown	7		55
Estrogen receptor status
Positive	154	74.4	1032	76.3
Negative	53	25.6	321	23.7
Unknown	39		191
Progesterone receptor status
Positive	138	67.0	826	61.5
Negative	68	33.0	518	38.5
Unknown	40		200

Abbreviations: CA15-3, carbohydrate antigen 15-3; CEA, carcinoembryonic antigen.